Ajanta Pharma

Ajanta Pharma delivered a strong Q4 FY26 with revenue of ₹1,422 croreCurrent reported value: ₹1,422 crore. No comparable prior figure is available in the source record. (+21Current reported value: 21. No comparable prior figure is available in the source record.% YoY) and PAT of ₹267 croreCurrent reported value: ₹267 crore. No comparable prior figure is available in the source record. (+18Current reported value: 18. No comparable prior figure is available in the source record.% YoY). Full-year revenue surpassed ₹5,000 croreCurrent reported value: ₹5,000 crore. No comparable prior figure is available in the source record. for the first time, driven by stellar US generics growth (+56% YoY in Q4) and robust India branded business (+14% FY26). EBITDA margin at 23Current reported value: 23. No comparable prior figure is available in the source record.% was impacted by mark-to-market forex losses of ₹42 crore; adjusted margins remain healthy. Management guided for FY27 revenue growth of 16-18%Current reported value: 16-18%. No comparable prior figure is available in the source record. and EBITDA margin of 27% ±1%Current reported value: 27% ±1%. No comparable prior figure is available in the source record., factoring in Middle East supply chain disruptions and higher freight costs. Key growth drivers include high double-digit growth in Asia and Africa branded generics, mid-single-digit US growth, and continued India outperformance. Risk: Prolonged Middle East conflict could further inflate logistics costs and pressure margins.